Navigation Links
SuperFect Transfection Reagent

The proven activated dendrimer for transfection of a broad range of cell lines

Features and benefits
  • Fast procedure and easy handling
  • Suitable for a broad range of cell lines
  • Transfection in the presence of serum (see figure "Serum and DNA Quantity vs. Transfection Efficiency")
  • High transient and stable transfection efficiencies
  • Excellent reproducibility due to precise size and defined shape of activated dendrimers

Serum and DNA Quantity vs. Transfection Efficiency



Influence of serum and DNA quantity on transfection using SuperFect Reagent. 2 x 104 COS-7 cells were seeded per well in 96-well plates one day prior transfection. Cells were transfected using 0.12.0 g of a beta-galactosidasereporter plasmid and 3 l SuperFect Reagent per well, in either the presence or absence of serum. Each bar represents the average efficiency from four replicates assayed 48 h post-transfection.

Principle

SuperFect Reagent consists of activated-dendrimer molecules with a defined spherical architecture (1). Branches radiate from a central core and terminate at charged amino groups which can then interact with negatively charged phosphate groups of nucleic acids (see figure "Activated-Dendrimer Structure"). SuperFect Reagent assembles DNA into compact structures (see figure "SuperFectDNA Interaction") that bind to the cell surface and are taken into the cell by nonspecific endocytosis. The reagent buffers the pH of the end osome, leading to pH inhibition of endosomal nucleases, which ensures stability of SuperFectDNA complexes.

Due to highly controlled chemical synthesis the activated-dendrimer molecules in SuperFect Reagent have a precise size and a defined shape. This ensures consistent transfection-complex formation and reproducible transfection results.

Activated-Dendrimer Structure

Schematic representation of an activated dendrimer (1). Note the highly branched structure.
SuperFectDNA Interaction
Model of the SuperFectDNA complex. SuperFect Reagent (purple balls) interacts with DNA (black) to form a ring-like (toroid-like) structure. The upper right section of the illustration shows naked DNA, the lower section shows the interaction between dendrimers and DNA inside the complex, and the upper left section shows the final complete coverage of DNA within the complex. Procedure

SuperFect Transfection Reagent is provided as a ready-to-use solution. The reagent is simply added to the DNA solution, mixed, and incubated for 510 minutes to allow SuperFectDNA complexes to form. The complexes are mixed with growth medium (which can contain serum and antibiotics), and added directly to the cells. After a 23 hour incubation, a medium change is performed and the cells are incubated for expression of the transfected gene.

Applications

SuperFect Re agent is suitable for transient and stable transfection of a broad range of cell lines (see figure "Transfection of Neuronal PC-12 Cells Using SuperFect Reagent"). A searchable list of cell lines successfully transfected using SuperFect Reagent, as well as customer-developed transfection protocols, is available at the Transfection Tools web site www.qiagen.com/transfectiontools/.

Transfection of Neuronal PC-12 Cells Using SuperFect Reagent


Expression of green fluorescent protein (GFP) in differentiated PC-12 cells 5 days post-transfection. 104105 cells previously stimulated with 50 ng/ml NGF were plated per 60 mm dish one day prior to transfection. Transient transfections were performed in 2 ml low-serum growth medium (DMEM plus 0.05% FBS) using 3 g of a GFP-reporter plasmid and 15 l SuperFect Reagent. (Data kindly provided by K. Kelly-Spratt, University of Texas Southwestern Medical Center, Dallas, TX, USA.)

High-throughput transfection

The application of recombinant DNA technology to fields such as drug discovery and development has led to an increased need for high-throughput transfection. Transfection using SuperFect Reagent requires minimal handling, making it highly suitable for high-throughput screening. SuperFect Reagent provides high transfection efficiencies, excellent reproducibility, and low cytotoxicity in high-throughput transfection, and is available in bulk quantities.

Cited References

1. Tang, M.X., Redemann, C.T., and Szoka, Jr., F.C. (1996) In vitro gene delivery by degraded polyamidoamine dendrimers. Bioconjugate Chem. 7, 703.



'"/>

Source:


Page: All 1 2 3

Related biology technology :

1. Highest Transfection Efficiency of an Endotoxin-Sensitive Mammalian Cell Line
2. Optimizing Transfection Conditions for Studying Signal Transduction Pathways
3. Transfection of Green Fluorescent Protein into Human Adrenalcarcinoma Cells
4. Improve Lipid- or Calcium Phosphate-Mediated Transfection of Human Dermal Fibroblasts
5. Versatile Transfection Reagent Offers Low Toxicity and Consistent Performance
6. Low-Toxicity, Lipid-Mediated Transfection of Mammalian Cells
7. Mycoplasma Contamination Reduces the Effect of Lipid-Mediated Transfection of Mammalian Cells
8. High-Efficiency Transfections Achieved with New Low-Toxicity Reagent
9. Efficient Transfection of Neurospora Crassa
10. Eppendorf Multiporator Transfection Protocols for Eukaryotic Cells
11. Efficient Transfection of Neurospora Crassa
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/23/2016)... -- The Prostate Cancer Foundation (PCF) is pleased to announce 24 new ... prostate cancer. Members of the Class of 2016 were selected from a pool ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , a ... $1 million in debt financing from Silicon Valley Bank ... automation and to advance its drug development efforts, as ... facility. "SVB has been an incredible strategic ... services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... STACS DNA ... Technical Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as a ... STACS DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further ...
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
Breaking Biology Technology:
(Date:4/19/2016)... , UAE, April 20, 2016 ... be implemented as a compact web-based "all-in-one" system solution ... the biometric fingerprint reader or the door interface with ... of modern access control systems. The minimal dimensions of ... ID readers into the building installations offer considerable freedom ...
(Date:4/13/2016)...  IMPOWER physicians supporting Medicaid patients in ... standard in telehealth thanks to a new partnership with ... IMPOWER patients can routinely track key health measurements, such ... and, when they opt in, share them with IMPOWER ... local retail location at no cost. By leveraging this ...
(Date:3/23/2016)... Massachusetts , March 23, 2016 /PRNewswire/ ... im Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung ... Xura, Inc. (NASDAQ: MESG ), ... bekannt, dass das Unternehmen mit SpeechPro zusammenarbeitet, ... aus der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, ...
Breaking Biology News(10 mins):